Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

AbbVie

Merck

Pfizer

Warren Buffett (Trades, Portfolio)'s Berkshire Hathaway (NYSE:BRK.A) (NYSE:BRK.B) filed its 13F report for the third quarter on Monday this week. The announcement revealed that the Oracle of Omaha made some exciting changes to his portfolio during the reported period, including several investments in pharmaceutical companies.

Has Buffett Become an Expert on Big Pharma?

Johnson & Johnson

Regeneron Pharmaceuticals

Sanofi

SPDR S&P Pharmaceuticals ETF

Zoetis

Pharmaceutical stocks help make the world go round. Without them, common ailments would plague our lives.

7 Pharmaceutical Stocks to Buy for 2021 and Beyond 

Let's see if Bristol Myers Squibb Company (BMY) stock is a good choice for value-oriented investors right now from multiple angles.

Should Value Investors Now Choose Bristol Myers (BMY) Stock?

NEW YORK--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE:BMY) announced today that it has successfully completed its acquisition of MyoKardia, Inc. in an all cash transaction for approximately $13.1 billion. With the completion of the acquisition, MyoKardia shares have ceased trading on the NASDAQ Global Select Market and MyoKardia is now a wholly-owned subsidiary of Bristol Myers Squibb. “We are excited to welcome MyoKardia colleagues to Bristol Myers Squibb. The MyoKardia team has revolutionized

Bristol Myers Squibb Completes Acquisition of MyoKardia, Strengthening Company's Leading Cardiovascular Franchise

AbbVie, Merck, Bristol Myers Squibb, and Pfizer are the latest beneficiaries of the "Buffett Effect." The quartet of pharmaceutical stocks jumped in pre-market trading on Tuesday after Warren Buffett's Berkshire Hathaway revealed on Monday that it invested in them last quarter. AbbVie, Merck, and Pfizer gained as much as 2%, and BMS rose as much as 3%, whereas benchmark S&P futures slid around 0.5%.

AbbVie, Merck, and Pfizer shares jump after Warren Buffett's Berkshire Hathaway reveals it bought them last quarter

Veeva Systems

PLEASANTON, Calif.--(BUSINESS WIRE)-- #VeevaSummitEU--Bristol Myers Squibb is adopting Veeva Vault PromoMats to deliver fast, compliant content across all digital channels to meet their customers' needs.

Veeva Vault PromoMats to Support Bristol Myers Squibb in Speeding Compliant Content to Market

PRINCETON, N.J.--(BUSINESS WIRE)--The BMS Foundation and National Medical Fellowships launch $100 million program to help increase diversity and inclusion in clinical trials

The Bristol Myers Squibb Foundation and National Medical Fellowships Launch $100 Million Program to Help Increase Diversity and Inclusion in Clinical Trials

Warren Buffett is ditching bank stocks and loading up on drug makers, according to Berkshire Hathaway's latest regulatory filing. The post Buffett's Berkshire Hathaway Buys New Stakes in Vaccine Makers, Cuts Banks appeared first on InvestorPlace.

Buffett's Berkshire Hathaway Buys New Stakes in Vaccine Makers, Cuts Banks

Berkshire Hathaway Inc (NYSE: BRK-A) (NYSE: BRK-B) Chairman Warren Buffett has invested in four large drugmakers as the world faces yet another wave of the raging COVID-19 pandemic. What Happened: Regulatory filings made with the United States Securities and Exchange Commission reveal that the legendary investor picked up shares worth nearly $136 million in drugmaker Pfizer Inc (NYSE: PFE) in the latest quarter.

Warren Buffett's Berkshire Bets On These Four Drugmakers Amid Pandemic

The Oracle of Omaha and his team opened new positions in the underperforming sector.

Warren Buffett Bought 4 Pharma Giants in Q3

Snowflake

T-Mobile US

Warren Buffett (Trades, Portfolio)'s $545.8 billion conglomerate, Berkshire Hathaway Inc. (NYSE:BRK.A)(NYSE:BRK.B), disclosed its equity portfolio for the third quarter of 2020 on Monday.

Warren Buffett Buys 6 Stocks in 3rd Quarter, Dumps Costco

Warren Buffett's Berkshire Hathaway is making a big bet on the health care sector at a time when the Covid-19 pandemic continues to be a major crisis in the United States.

Warren Buffett's Berkshire Hathaway makes big bets on drug stocks

Warren Buffett's Berkshire Hathaway invested in AbbVie, Bristol-Myers Squibb, Merck, and Pfizer in the third quarter. The billionaire investor's company disclosed the new holdings in a regulatory filing on Monday. Berkshire boasted stakes worth more than $1.8 billion in each of AbbVie, Bristol Myers Squibb, and Merck as of September 30. It also owned $136 million of Pfizer stock. Buffett and his team also trimmed their Apple stake, which is easily the most valuable holding in their stock portfolio. Visit Business Insider's homepage for more stories. Warren Buffett's Berkshire Hathaway plowed billions of dollars into Pfizer, Merck, and other pharmaceutical stocks in the third quarter, a regulatory filing revealed on Monday.

Warren Buffett's Berkshire Hathaway reveals stakes in AbbVie, Merck, Pfizer, and other 'big pharma' stocks

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Provides Regulatory Update on Lisocabtagene Maraleucel (liso-cel)

Bristol Myers Squibb Provides Regulatory Update on Lisocabtagene Maraleucel (liso-cel)

Warren Buffett's Berkshire Hathaway Inc said on Monday it has begun investing in four large drugmakers.

Buffett's Berkshire invests in several big drugmakers

Aspen Technology Inc

Alibaba

British American Tobacco

Cboe Global Markets

Cisco Systems

eBay

McKesson

Altria

Oracle

Polaris

Philip Morris

SEI Investments

T. Rowe Price Group

Optimism about effective vaccines coming soon have sent the market back to record highs, ending the pullback. For the rest of the year, the pandemic is expected to continue getting worse. JPMorgan estimates a 20% to 25% probability of a double-dip recession and a 22% bear market.

The 15 Highest Quality Blue Chips To Buy With Market At All-Time Highs

Home Depot

Microsoft

Target

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

Walmart

The election is finally over, and investors are euphoric about Pfizer and BioNTech's COVID vaccine candidate. As markets seem to see-saw based on sentiment, quality companies that pay solid dividends are always a great way to go.

Top Dividend Stocks For November

SYDNEY--(BUSINESS WIRE)-- #clinicaltrials--Noxopharm announces pilot study with Bristol Myers Squibb's product

Noxopharm Announces Pilot Study With Bristol Myers Squibb's Product

NEW YORK--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in Wolfe Research's 2nd Annual Virtual Healthcare Conference

Bristol Myers Squibb to Participate in Wolfe Research's 2nd Annual Virtual Healthcare Conference

Amgen

Anthem

Cigna

As Mr. Valuation, I find myself constantly reminding investors that value investing requires patience. However, value investing also requires the willingness to get your money in front of attractive valuation when it is discovered. Trying to time your purchases perfectly can just as easily cause you to miss out on significant gains as it is to participate in them. More directly stated, significant undervaluation can stimulate strong pent-up demand causing stock prices to rise rapidly. Therefore, if you are not already in front of those advances, you can miss out on a lot of profit and opportunity.

5 Leading Healthcare Stocks Surging On Pent-Up Demand

Citigroup

GlaxoSmithKline

Seaboard

Kahn Brothers (Trades, Portfolio) has released its third-quarter portfolio. Throughout the portfolio holdings were reduced or sold completely, with the largest changes coming from Merck & Co. Inc. (NYSE:MRK), Bristol-Myers Squibb Company (NYSE:BMY), GlaxoSmithKline PLC (NYSE:GSK), Citigroup Inc. (NYSE:C) and Seaboard Corp. (SEB).

Kahn Brothers' Biggest 3rd-Quarter Sells

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ACR20--BMS Presents Late-Breaking Phase 2 Data Demonstrating the Safety and Efficacy of Deucravacitinib (BMS-986165) in Patients with Psoriatic Arthritis.

Bristol Myers Squibb Presents Late-Breaking Phase 2 Data Demonstrating the Safety and Efficacy of Deucravacitinib (BMS-986165) in Patients with Psoriatic Arthritis

Painful sell-off in BMY.RT yesterday after a confusing Bristol-Myers conference call. The call was really awful because BMY basically said two facilities need to be inspected, one isn't and they aren't scheduled.

Bristol-Myers Squibb Contingent Value Rights: Inclined To Believe There's Still Value

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--BMS Receives European Commission Approval for Opdivo Plus Yervoy with Two Cycles of Chemotherapy for First-Line Treatment of Metastatic NSCLC

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for First-Line Treatment of Metastatic Non-Small Cell Lung Cancer

The credit mainly lies with the big drugmaker's acquisition of Celgene last year.

News for Bristol-Myers Stock (BMY)